NASDAQ:OTIC Otonomy - OTIC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Otonomy, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.11 0.00 (0.00%) (As of 03/27/2023 12:57 PM ET) Add Compare Share Share Today's Range$0.11▼$0.1150-Day Range$0.10▼$0.1252-Week Range$0.06▼$2.54Volume97,908 shsAverage Volume1.01 million shsMarket Capitalization$7.61 millionP/E RatioN/ADividend YieldN/APrice Target$3.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Otonomy MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside2,807.0% Upside$3.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 stars 3.2 Analyst's Opinion Consensus RatingOtonomy has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.25, Otonomy has a forecasted upside of 2,807.0% from its current price of $0.11.Amount of Analyst CoverageOtonomy has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for OTIC. Previous Next 0.0 Dividend Strength Dividend YieldOtonomy does not currently pay a dividend.Dividend GrowthOtonomy does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OTIC. Previous Next 1.7 News and Social Media Coverage News SentimentOtonomy has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Otonomy this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Otonomy to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Otonomy insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.09% of the stock of Otonomy is held by insiders.Percentage Held by Institutions41.23% of the stock of Otonomy is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Otonomy is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Otonomy is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOtonomy has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Otonomy (NASDAQ:OTIC) StockOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Read More Receive OTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter. Email Address OTIC Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comOtonomy (NASDAQ:OTIC) Receives New Coverage from Analysts at StockNews.comJanuary 23, 2023 | finance.yahoo.comOtonomy, Inc. (OTIC) Stock Historical Prices & Data - Yahoo FinanceMarch 27, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. December 21, 2022 | finanznachrichten.deOtonomy, Inc.: Otonomy Provides Corporate UpdateDecember 19, 2022 | finance.yahoo.comOtonomy Provides Corporate UpdateNovember 29, 2022 | investorplace.comWhy Is Otonomy (OTIC) Stock Up 97% Today?November 10, 2022 | finance.yahoo.comOtonomy Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 6, 2022 | reuters.comOTIC.OQ - Otonomy Inc | Stock Price & Latest News | ReutersMarch 27, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. October 13, 2022 | investing.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% By Investing.com - Investing.comOctober 13, 2022 | finance.yahoo.comLianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial - Yahoo FinanceOctober 13, 2022 | streetinsider.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% - StreetInsider.comOctober 13, 2022 | benzinga.comOtonomy shares are trading lower after the company reported higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline. - Otonomy (NASDAQ:OTIC) - BenzingaOctober 13, 2022 | benzinga.comWhy Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday’s Mid- - BenzingaOctober 13, 2022 | globenewswire.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - GlobeNewswireOctober 13, 2022 | finance.yahoo.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comOtonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing LossOctober 7, 2022 | reuters.comOTIC.O - Otonomy Inc | Stock Price & Latest News | ReutersSeptember 9, 2022 | streetinsider.comForm SC 13G/A OTONOMY, INC. Filed by: FEDERATED HERMES, INC. - StreetInsider.comSeptember 1, 2022 | finance.yahoo.comAGTC to Participate in Upcoming Investor Conferences - Yahoo FinanceAugust 6, 2022 | benzinga.comShort Volatility Alert: Otonomy, Inc. - BenzingaAugust 2, 2022 | seekingalpha.comOTIC stock downgraded at H.C. Wainwright as tinnitus candidate fails (NASDAQ:OTIC) - Seeking AlphaAugust 2, 2022 | uk.investing.comDaily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial By Benzinga - Investing.com UKAugust 2, 2022 | marketwatch.comOtonomy Shares Plumb New Depths on Failure of Lead Program >OTIC - MarketWatchAugust 1, 2022 | seekingalpha.comVirax, Aethlon top healthcare gainers; while Otonomy, Kazia lead losers' pack - Seeking AlphaAugust 1, 2022 | finance.yahoo.comOtonomy Shares Sink After Stopping Mid-Stage Tinnitus StudyAugust 1, 2022 | benzinga.comOtonomy Reports Results From Phase 2 Clinical Trial Of OTO-313 In Patients With Tinnitus; Co. Reports 'OT - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter. Email Address OTIC Company Calendar Last Earnings11/10/2021Today3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OTIC CUSIPN/A CIK1493566 Webwww.otonomy.com Phone(619) 323-2200Fax619-291-9190Employees51Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.25 High Stock Price Forecast$6.00 Low Stock Price Forecast$0.50 Forecasted Upside/Downside+2,827.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-137.86% Return on Assets-68.50% Debt Debt-to-Equity RatioN/A Current Ratio1.74 Quick Ratio1.74 Sales & Book Value Annual Sales$130,000.00 Price / Sales58.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.11Miscellaneous Outstanding Shares68,530,000Free Float67,780,000Market Cap$7.61 million OptionableOptionable Beta1.58 Key ExecutivesPaul E. CayerPresident, CFO, Secretary & Chief Business OfficerAnna StepannenkoVice President -Technical operationsFabrice PiuVice President-Research & Preclinical DevelopmentDavid SkarinskyVice President-ClinicalJeffery J. AndersonVice President-Clinical SciencesKey CompetitorsCyclacel PharmaceuticalsNASDAQ:CYCCEnsysce BiosciencesNASDAQ:ENSCAridis PharmaceuticalsNASDAQ:ARDSMidatech PharmaNASDAQ:MTPAytu BioPharmaNASDAQ:AYTUView All CompetitorsInsidersVickie L CappsSold 42,242 sharesTotal: $4,224.20 ($0.10/share)David Allen WeberSold 11,243 sharesTotal: $27,095.63 ($2.41/share)Robert Michael Savel IISold 3,325 sharesTotal: $8,013.25 ($2.41/share)View All Insider Transactions OTIC Stock - Frequently Asked Questions Should I buy or sell Otonomy stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares. View OTIC analyst ratings or view top-rated stocks. What is Otonomy's stock price forecast for 2023? 3 equities research analysts have issued 12-month target prices for Otonomy's shares. Their OTIC share price forecasts range from $0.50 to $6.00. On average, they anticipate the company's share price to reach $3.25 in the next year. This suggests a possible upside of 2,827.9% from the stock's current price. View analysts price targets for OTIC or view top-rated stocks among Wall Street analysts. How have OTIC shares performed in 2023? Otonomy's stock was trading at $0.0871 at the start of the year. Since then, OTIC stock has increased by 27.4% and is now trading at $0.1110. View the best growth stocks for 2023 here. How were Otonomy's earnings last quarter? Otonomy, Inc. (NASDAQ:OTIC) released its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). During the same period in the previous year, the firm posted ($0.22) earnings per share. What other stocks do shareholders of Otonomy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie (). What is Otonomy's stock symbol? Otonomy trades on the NASDAQ under the ticker symbol "OTIC." Who are Otonomy's major shareholders? Otonomy's stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Allen Weber, Jay Lichter, Robert Michael Savel II and Vickie L Capps. View institutional ownership trends. How do I buy shares of Otonomy? Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Otonomy's stock price today? One share of OTIC stock can currently be purchased for approximately $0.11. How much money does Otonomy make? Otonomy (NASDAQ:OTIC) has a market capitalization of $7.61 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. How can I contact Otonomy? Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190. This page (NASDAQ:OTIC) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.